Plural Chalcogens Bonded Directly To The Hetero Ring Patents (Class 549/400)
-
Publication number: 20120264820Abstract: A compound, pharmaceutical composition and method for the treatment of mammals wherein the active therapeutic agent is a compound having the structure: wherein: R1 is an electronegative substituent, R2 is R1 or alkyl, R3 is H or O-alkyl, R4 and R5 are the same or different and are alkyl and R6 is H or OH.Type: ApplicationFiled: December 31, 2007Publication date: October 18, 2012Inventors: Kinfe Redda, Chavonda Janeebra Mills, Nelly Maleeva
-
Publication number: 20120258170Abstract: A co-crystal composition comprised of Quercetin and at least one antidiabetic agent acts as a combination drug having unique physical properties and biological activity, which differ from both Quercetin in pure form and the at least one antidiabetic agent in pure form. The co-crystal composition may comprise quercetin and metformin. The co-crystals of quercetin and metformin may be prepared by grinding the compounds, and used in pharmaceutical compositions comprising these co-crystals. Co-crystal compositions of quercetin and Metformin may be used in combination with other anti-diabetic agents, including DPP-IV inhibitors.Type: ApplicationFiled: March 19, 2012Publication date: October 11, 2012Applicant: Nutracryst Therapeutics Private LimitedInventors: Anil Kumar KRUTHIVENTI, Iqbal Javed, Satyanarayana Reddy Jaggavarapu, RaviKumar Nagalapalli, Ganesh Saraswatula Viswanadha, Solomon Kamalakaran Anand
-
Patent number: 8273905Abstract: Compounds corresponding to formula I, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n have the meanings given in the description, and also a process for the preparation of these compounds and intermediate products of this process. Furthermore, pharmaceutical compositions comprising the compounds of Formula I and related methods of treatment.Type: GrantFiled: February 27, 2009Date of Patent: September 25, 2012Assignee: Abbott Products GmbHInventors: Brian Moloney, Lester Marrison, Dieter Ziegler, Michael Mlinaric, Christiane Boecker, Reinhard Brueckner, Michael Weske, Klaus Witte, Yvan Fischer
-
Patent number: 8263790Abstract: A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.Type: GrantFiled: June 1, 2011Date of Patent: September 11, 2012Assignees: Children's Hospital Medical Center, Girindus America, Inc.Inventors: Kenneth David Reginald Setchell, Victor Dmitrievich Sorokin
-
Patent number: 8252835Abstract: Provided herein in certain embodiments are compounds, pharmaceutical compositions and methods for modulating the functions of estrogen receptor alpha 36, for preventing and/or treating diseases related to estrogen receptor alpha 36, for preventing and/or treating respiratory diseases such as asthma, for inducing cell death and/or inhibiting cell proliferation and for preventing and/or treating diseases involving abnormal cell proliferation such as cancers.Type: GrantFiled: October 23, 2007Date of Patent: August 28, 2012Assignee: Shenogen Pharma Group Ltd.Inventors: Jin Li, Kun Meng
-
Publication number: 20120213842Abstract: The subject invention relates to novel micoparticulate and soluble forms of flavonoids, and their synthesis. The invention also includes novel formulations of such flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations.Type: ApplicationFiled: October 22, 2010Publication date: August 23, 2012Inventor: Philip J. Birbara
-
Publication number: 20120208845Abstract: The present invention relates to agonists and antagonists of the human bitter-taste receptor hTAS2R49. The invention also relates to methods for identifying further molecules that suppress or enhance hTAS2R49-mediated bitter taste transduction or bitter taste response and uses thereof.Type: ApplicationFiled: July 28, 2010Publication date: August 16, 2012Inventors: Claudia Batram, Wolfgang Meyerhof
-
Publication number: 20120129923Abstract: Disclosed herein is synergistic pharmaceutical co-crystals composition comprising Quercetin and an antidiabetic agent(s) as combination drug that have unique physical properties and biological activity which differ from the active agent in pure form. The invention further discloses process for preparation of the same and pharmaceutical compositions comprising these synergistic co-crystals.Type: ApplicationFiled: October 30, 2009Publication date: May 24, 2012Applicant: NUTRACRYST THERAPEUTICS PRIVATE LIMITEDInventors: Anil Kumar Kruthiventi, Iqbal Javed, Satyanarayana Reddy Jaggavarapu, RaviKumar Nagalapalli, Ganesh Saraswatula Viswanadha, Solomon Kamalakaran Anand
-
Patent number: 8178702Abstract: A composition comprising compound of formula I, a process for preparing the composition comprising compound of formula I, methods of authentication for an article comprising compound of formula I or compound of formula II, authentication technology for polymer based articles comprising compound of formula I or formula II, methods of facilitating such authentication and method of making articles capable of authentication.Type: GrantFiled: May 16, 2008Date of Patent: May 15, 2012Assignee: Sabic Innovative Plastics IP B.V.Inventors: Yogendrasinh Chauhan, Mahesh Chaudhari, Adil Dhalla, Sriramakrishna Maruvada, Shantaram Naik, Vandita Pai-Paranjape, Philippe Schottland, Ganapati Shankarling, Kiran Puthamane, Meerakani Sait
-
Patent number: 8143428Abstract: Compounds of Formula I: wherein R1, R2, M, Q and n are as defined herein, are useful as antiproliferative agents including, for example, as anticancer agents.Type: GrantFiled: June 8, 2005Date of Patent: March 27, 2012Assignee: Temple University-Of The Commonwealth System of Higher EducationInventors: E. Premkumar Reddy, M. V. Ramana Reddy
-
Publication number: 20120046353Abstract: The present invention relates to a Cleistocalyx operculatus-derived compound having inhibitory activity against neuraminidase and to a composition for preventing and treating diseases caused by avian and swine influenza viruses and novel influenza viruses, comprising the compound as an active ingredient.Type: ApplicationFiled: November 24, 2010Publication date: February 23, 2012Applicant: CHOONG ANG VACCINE LAB.Inventors: Injoong YOON, Eunhee KIM, Hwan-won CHOI, Won Keun OH, Trong Tuan DAO, Phuong Thien THUONG
-
Patent number: 8110599Abstract: The present application relates to a novel AMPelopsin unsaturated sodium salt compound (AMP-Na), a method for preparing the same and the applications thereof. The physicochemical properties of AMP-Na according to the present application are significantly altered compared to those of AMPelopsin (AMP). AMP-Na shows significantly reduced toxicity than AMP as evidenced by the in vivo acute toxicity studies. As demonstrated by pharmacological evaluation, AMP-Na exhibits synergistic action when administered in combination with clinically used anti-cancer drugs, therefore reducing their dosages without compromising their therapeutic effects.Type: GrantFiled: March 31, 2006Date of Patent: February 7, 2012Inventor: Fulin Fan
-
Patent number: 8017649Abstract: Novel flavonoid compounds having anti-oxidant activity are described. The compounds and compositions have been shown to exhibit anti-oxidant properties and are particularly useful in the treatment of ischemia and reperfusion injuries. The invention also describes a method to chemically synthesize such flavonoid compounds and test their efficacy. Such compounds and corresponding pharmaceutically acceptable derivatives and/or salts have uses in the areas of pharmaceuticals, nutraceutical, and veterinary applications.Type: GrantFiled: March 10, 2006Date of Patent: September 13, 2011Assignee: Howard Florey Institute of Experimental Physiology and MedicineInventors: Bevyn Jarrott, Clive Newton May, Owen Llewellyn Woodman, Gregory James Dusting
-
Patent number: 8008344Abstract: The invention relates to a compound represented by the following formula (I): and pharmaceutically acceptable salts, stereoisomers, enantiomers, prodrugs and solvates thereof. The compounds are useful as an agent for enhancing the neurite outgrowth and preventing or treating of diseases associated with HDAC in particular, tumor or cell proliferative diseases. In particular, the compounds of the invention can be used as an agent for anti-neurodegenerative diseases and human spinal muscular atrophy (SMA).Type: GrantFiled: September 14, 2007Date of Patent: August 30, 2011Assignee: Naturewise Biotech and Medicals CorporationInventors: Chung-Yang Huang, Chia-Nan Chen, Wei-Jan Huang, Chih-Hsiang Huang, Li-Ling Chi, Chiou-Ping You
-
Publication number: 20110190514Abstract: Novel pyrone analogs are described which can enhance the effectiveness of a therapeutic agent when administered and/or reduce side effects caused by the administration of a therapeutic agent.Type: ApplicationFiled: September 8, 2010Publication date: August 4, 2011Applicant: Limerick BioPharma, Inc.Inventors: Wendye Robbins, Ving Lee
-
Publication number: 20110155242Abstract: A fluorescent material of Formula (I) is provided. In Formula (I), all the variables thereof are described in the specification. The invention also provides a solar cell with the disclosed fluorescent material. The solar cell with the fluorescent material includes a solar cell and a fluorescent layer including the disclosed fluorescent material of Formula (I) coating on the solar cell.Type: ApplicationFiled: April 3, 2010Publication date: June 30, 2011Applicants: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE, NEO SOLAR POWER CORPInventors: Ching-Yen Wei, Yi-Ling Chen, Wei-Jen Liu, Yi-Chen Chiu, Yang-Fang Chen, Kao-Chiang Hsu, Yu-Wei Tai, Chia-Ching Wang, Meng-Hsiu Wu
-
Publication number: 20110144195Abstract: Two distinct methods are disclosed and claimed for synthesizing glyceollin I plus glyceollin II as a mixture and as their pure forms. Stereochemical isomers and various synthetic intermediates are also synthesized and claimed for their novel compositions of matter. All compounds and their mixtures are claimed for use in formulations that are useful to treat or prevent cancer, or that have utility as selective estrogen receptor modulators, such formulations including enhanced or medical foods, dietary supplements and ethical pharmaceutical agents.Type: ApplicationFiled: March 3, 2009Publication date: June 16, 2011Inventors: Paul W. Erhardt, Rahul Khupse, Jeffrerey G. Sarver, Thomas E. Cleveland, Stephen M. Boue, Thomas E. Wiese, Matthew E. Burow, John A. McClachlan
-
Patent number: 7960573Abstract: A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.Type: GrantFiled: May 4, 2009Date of Patent: June 14, 2011Assignees: Children's Hospital Medical Center, Girindus America, Inc.Inventors: Kenneth David Reginald Setchell, Victor Dmitrievich Sorokin
-
Publication number: 20110124832Abstract: Provided is a low-cost, environmentally friendly living radical polymerization catalyst having high activity. The catalyst is used for a living radical polymerization method, and contains a central element consisting of oxygen and at least one halogen atom bound to the central element. Furthermore, an alcohol compound can be used as a catalyst precursor. By polymerizing a monomer in the presence of the catalyst, a polymer having narrow molecular weight distribution can be obtained, and the cost of the living radical polymerization can be remarkably reduced. The present invention is significantly more environmentally friendly and economically excellent than conventional living radical polymerization methods, due to advantages of the catalyst such as low toxicity of the catalyst, low amount of the catalyst necessary, high solubility of the catalyst, mild reaction conditions, and no coloration/no odor (which do not require a post-treatment for a molded article), and the like.Type: ApplicationFiled: February 6, 2009Publication date: May 26, 2011Applicant: KYOTO UNIVERSITYInventors: Atsushi Goto, Takeshi Fukuda, Yoshinobu Tsujii
-
Publication number: 20110112181Abstract: Disclosed is a composition for modulating the release of a neurotransmitter, which includes naturally extracted polyphenols as an active ingredient. The disclosed composition suppresses the formation of a SNARE complex, thereby modulating the release of a neurotransmitter, and thus can be used as a modulator for a reaction within a cell related to the SNARE complex. Such an inhibitor of the SNARE complex formation can be used as a composition for reducing wrinkles and relieving pain.Type: ApplicationFiled: March 12, 2008Publication date: May 12, 2011Applicant: SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATIONInventors: Dae-Hyuk Kweon, Yeon-Kyun Shin, Chang-Hwa Jung, Yoo-Soo Yang
-
Publication number: 20110041725Abstract: Methods and compositions are provided for the reduction of fouling of objects present in marine environments. The methods and compositions include anticoagulants, such as, for example, glycosaminoglycans, coumarin-type molecules, metal chelators, plasminogen activators and platelet inhibitors. The methods include reducing marine fouling, comprising incorporating an anticoagulant compound into a marine coating. In addition, the methods include identifying compounds useful for reducing marine fouling, comprising measuring either blood coagulation or barnacle cement polymerization in the presence and absence of the compound, wherein a reduction in the blood coagulation or the barnacle cement polymerization in the presence of the compound identifies the compound as useful for reducing marine fouling. The coagulation or the polymerization can be measured by a serine protease activity or a transglutaminase activity.Type: ApplicationFiled: June 13, 2008Publication date: February 24, 2011Inventors: Daniel Rittschof, Gary H. Dickinson, Beatriz Orihuela de Diaz, Eric R. Holm
-
Publication number: 20110046378Abstract: Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's DiseaseType: ApplicationFiled: February 17, 2009Publication date: February 24, 2011Applicant: SIEMENS MEDICAL SOLUTIONS USA, INC.Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Qianwa Liang, Brian A. Duclos, Wei Zhang, Peter J.H. Scott, Kai Chen, Zhiyong Gao, Tieming Zhao, Vani P. Mocharla, Dhanalakshmi Kasi, Gang Chen, Eric Wang, Anjana Sinha, Chunfang Xia, Henry Clifton Padgett, Farhad Karimi
-
Publication number: 20110028742Abstract: Provided are: method of producing a sulfur-containing proanthocyanidin oligomer by reducing the molecular weight of proanthocyanidin in plants so that they can be readily absorbed through the intestine of an organism; and a health food composition and a pharmaceutical composition which contain the resultant sulfur-containing proanthocyanidin oligomer as an active ingredient and which are useful for treating and preventing various lifestyle-related diseases and brain diseases caused by generation of active oxygen species as well as for preventing aging.Type: ApplicationFiled: October 6, 2010Publication date: February 3, 2011Applicants: AMINO UP CHEMICAL CO., LTD., USAIEN PHARMACEUTICAL CO., LTD.Inventors: Gen-ichiro NONAKA, Buxiang SUN, Lan YUAN, Takashi NAKAGAWA, Hajime FUJII, Young-Joon SURH
-
Patent number: 7880021Abstract: 3-hydroxyflavone derivatives are useful in the detection and the quantification of cell apoptosis. Such derivatives are also useful as fluorescent probes in studying lipid asymmetry of cell plasma membrane and in detecting apopoptic cells. The derivatives can be used to monitor the evolution of diseases involving cell apoptosis.Type: GrantFiled: October 11, 2006Date of Patent: February 1, 2011Assignees: Centre National de la Recherche Scientifique (CNRS), Universite Louis Pasteur (Strasbourg I)Inventors: Yves Mely, Andrey Klymchenko, Oleksandr Demchenko, Vasyl Shynkar
-
Publication number: 20110021792Abstract: Provided are: method of producing a sulfur-containing proanthocyanidin oligomer by reducing the molecular weight of proanthocyanidin in plants so that they can be readily absorbed through the intestine of an organism; and a health food composition and a pharmaceutical composition which contain the resultant sulfur-containing proanthocyanidin oligomer as an active ingredient and which are useful for treating and preventing various lifestyle-related diseases and brain diseases caused by generation of active oxygen species as well as for preventing aging.Type: ApplicationFiled: October 6, 2010Publication date: January 27, 2011Applicants: Amino Up Chemical Co., Ltd., Usaien Pharmaceutical Co., Ltd.Inventors: Gen-ichiro NONAKA, Buxiang SUN, Lan YUAN, Takashi NAKAGAWA, Hajime FUJII, Young-Joon SURH
-
Publication number: 20110003861Abstract: 2-aryl and 2-heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives of formula (I) useful as pharmacological agents for the treatment of arthritis, cancer and related pain.Type: ApplicationFiled: March 6, 2008Publication date: January 6, 2011Applicant: ROTTAPHARM S.P.A.Inventors: Antonio Giordani, Ilario Verpilio, Sabrina Pucci, Roberto Artusi, Gianfranco Caselli, Marco Lanza, Laura Mennuni, Francesco Makovec, Lucio Claudio Rovati
-
Patent number: 7863323Abstract: A compound of the formula (I): wherein R is selected from the group consisting of H, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl and acyl, each of which may be optionally substituted; R1 is an organic moiety that is capable of being converted into a charged group; each X and Y is independently selected from the group consisting of H, halogen, —CN, —NO2, —CF3, —OCF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, arylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, phenoxy, benzyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, —COOH, —COR2, —COOR2, —CONHR2, —NType: GrantFiled: October 27, 2006Date of Patent: January 4, 2011Assignee: The University of MelbourneInventors: Spencer J. Williams, Owen L. Woodman, SuWan Yap
-
Publication number: 20100305313Abstract: The present invention relates to a process for the extraction of plant ingredients, which comprises a) comminuting plant material b) adding a solvent to the comminuted plant material c) subjecting the mixture of comminuted plant material and solvent to an ultrahigh temperature treatment at 95-150° C. over a period of 5-300 seconds.Type: ApplicationFiled: December 16, 2008Publication date: December 2, 2010Applicant: Bayer CropScience AGInventors: Michael Baeuerlein, Joseph Miller
-
Patent number: 7838553Abstract: The present invention is directed to novel benzopyran derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.Type: GrantFiled: August 30, 2006Date of Patent: November 23, 2010Assignee: Janssen Pharmaceutica NVInventors: Xuqing Zhang, Xiaojie Li, Zhihua Sui
-
Publication number: 20100286255Abstract: The invention relates to extracting secoisolariciresinol and dihydroquercetin from wood. The inventive method consists in extracting disintegrating wood of a screen area by means of a non-splitting mixture of organic solvent and water, the solvent content ranging from 50 to 75%, in such a way that a secoisolariciresinol and dihydroquercetin-containing extract is obtained, and in processing said extract by removing the solvent in such a way that a final secoisolariciresinol and dihydroquercetin-containing mixture is obtained.Type: ApplicationFiled: March 26, 2008Publication date: November 11, 2010Inventors: Nikolay Eduardovich Nifantiev, Dmitrl Vladimirovich Yashunsky, Vladimir Mikhailovich Menshov, Yury Evgenievich Tsvetkoy, Dmitri Evgenievich Tsvetkov
-
Publication number: 20100279961Abstract: The invention relates to a pharmaceutical composition comprising a glucuronate, glucoside, and/or sulfo conjugate of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, or such a conjugate of a derivative of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, or a physiologically well tolerated salt of such a conjugate.Type: ApplicationFiled: June 17, 2008Publication date: November 4, 2010Applicant: ANALYTICON DISCOVERY GMBHInventors: Lutz Müller-Kuhrt, Christian Mang, Michael Thiede
-
Publication number: 20100267132Abstract: The invention is directed to compounds of Formula (I) or salts thereof. The invention is also directed to use of the compounds of formula (I) in the in vitro preservation of living animal cells. The living cells can be isolated cells, such as stem cells, or groups of cells such as tissue or an organ.Type: ApplicationFiled: April 9, 2010Publication date: October 21, 2010Applicant: ANTOXIS LIMITEDInventors: Donald Barton McPhail, Graeme James Cook, Andrew Scott Johnstone
-
Publication number: 20100266523Abstract: The invention relates to compositions of polyphenol derivatives, characterised in that said polyphenols contain monomers, oligomers or polymers of units of the formula (I), wherein said units are characterised by the simultaneous presence of a phloroglucinol-type core (core A) and of a catechol-type core (core B) bonded together by a segment of 3 carbons such as C, said derivatives being over-activated in terms of nucleophilic power by the alkylation of at least one phenol function of each constituent monomer unit, and stabilised by the esterification of all the others with mixtures of fatty acids in proportions representing those of vegetable oils mainly consisting of AGI. These compositions can particularly be used in cosmetics, nutrition and therapy.Type: ApplicationFiled: November 17, 2008Publication date: October 21, 2010Inventor: Joseph Vercauteren
-
Publication number: 20100234311Abstract: This present provides kaempferol-3-(2-E,3-Z-di-p-coumaroyl)-rhamnoside, kaempferol-3-(2-Z-3-E-di-p-coumaroyl)-rhamnoside, and kaempferol-3-(2,3-di-Z-p-coumaroyl)-rhamnoside compounds useful as a new class of anti-bacterial agents. These compounds are extracted from Platanus occidentalis. These compounds were found to exhibit anti-bacterial activity against methicillin resistant Staphylococcus aureus (MRSA).Type: ApplicationFiled: March 16, 2010Publication date: September 16, 2010Applicant: The University of MississippiInventors: Mark T. Hamann, Mohamed Ali
-
Publication number: 20100151508Abstract: Flavonoid-type compounds of the Formula (II); in which R1 is alkyl C2 to C20, R2, R3, R4 and R5 are any one or more of hydrogen, alkyl, alkenyl, alkynyl, phenyl or benzyl, especially 7-decyl-3-hydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopy-ran-4-one or 7-ethyl-3-hydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one provide fluorescent probes and antioxidants, and are useful in discriminating healthy and stressed cells.Type: ApplicationFiled: November 21, 2007Publication date: June 17, 2010Applicant: THE ROBERT GORDON UNIVERSITYInventors: Paul Kong Thoo Lin, Charles Stuart Bestwick
-
Patent number: 7727511Abstract: Provided herein are agents that bind to soluble beta-amyloid. Also provided are in vivo and in vitro methods for detecting soluble beta-amyloid in a sample that may include brain tissue.Type: GrantFiled: December 11, 2006Date of Patent: June 1, 2010Assignee: General Electric CompanyInventors: Tiberiu Mircea Siclovan, Michael Christopher Montalto, Tun Chiao Hubert Lam, Eric Dustin Agdeppa, Amy Casey Williams, Cristina Tan Hehir
-
Patent number: 7714150Abstract: Compounds corresponding to formula I, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n have the meanings given in the description, and also a process for the preparation of these compounds and intermediate products of this process. Furthermore, pharmaceutical compositions comprising the compounds of Formula I and related methods of treatment.Type: GrantFiled: April 10, 2006Date of Patent: May 11, 2010Assignee: Solvay Pharmaceuticals GmbHInventors: Brian Moloney, Lester Marrison, Dieter Ziegler, Michael Mlinaric, Christiane Boecker, Reinhard Brueckner, Michael Weske, Klaus Witte, Yvan Fischer
-
Patent number: 7671220Abstract: The present invention relates to methods for the preparation of 3,3-dialky 4-chromanones, and particularly to the preparation of 6-fluoro-3,3-dimethyl-2,3-dihydro-4H-chromen-4-one and 3,3-dimethyl-2,3-dihydro-4H-chromen-4-one. In some embodiments, the processes include reaction of a 4-chromanone compound with an alkyl halide in the presence of a metal alkoxide at low temperature.Type: GrantFiled: February 15, 2006Date of Patent: March 2, 2010Assignee: WyethInventors: Ayako Yamashita, Emily B. Norton, Jaechul Shim, Cilien S. Hanna
-
Patent number: 7666902Abstract: The subject invention provides anticoagulant compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R3, n and Ar are as defined herein. The compounds of the subject invention can be used to treat at-risk populations thereby bringing relief of symptoms, improving the quality of life, preventing acute and long-term complications, reducing mortality and treating accompanying disorders. The invention further comprises pharmaceutical compositions comprising the compounds and salts of the invention, as well as methods of using the compounds, salts, and compositions of the invention.Type: GrantFiled: July 16, 2007Date of Patent: February 23, 2010Assignee: ARYx Therapeutics, Inc.Inventors: Pascal Druzgala, Cyrus Becker
-
Patent number: 7635778Abstract: A composition comprising compound of formula I, a process for preparing the composition comprising compound of formula I, methods of authentication for an article comprising compound of formula I or compound of formula II, authentication technology for polymer based articles comprising compound of formula I or formula II, methods of facilitating such authentication and method of making articles capable of authentication.Type: GrantFiled: December 17, 2004Date of Patent: December 22, 2009Assignee: SABIC Innovative Plastics IP B.V.Inventors: Yogendrasinh Chauhan, Mahesh Chaudhari, Adil Dhalla, Sriramakrishna Maruvada, Shantaram Naik, Vandita Pai-Paranjape, Philippe Schottland, Ganapati Shankarling, Kiran Puthamane, Meerakani Sait
-
Publication number: 20090269793Abstract: The present invention relates a compound of formula (1) wherein: —R1 represents a linear alkyl group of 4 to 20 carbon atoms; —Y represents a linear alkyl group of 1 to 5 carbon atoms or a group of formula —R—O—R?—, —R—CO—R?— or —R—CO—NH—R?—, in which R represents a linear alkyl group of 1 to 3 carbon atoms, R? represents a linear alkylene group of 0-3 carbon atoms, Y being linked to the bicycle in position 6 or 7; -Z represents a linear alkyl chain of 3 or 4 carbon atoms; -A represents an oxygen atom, a sulphur atom, or a —NH group, or an amminoalkyl group —NR? in which R? represents an alkyl group of 1 to 20 carbon atoms; —Ar represents an aromatic cycle or polycycle consisting of 6 to 14 carbon atoms, or an aromatic heterocycle, said heterocycle containing 4, 5 or 6 carbon atoms and at least one heteroatom selected in the group consisting of N, S, and O, or a condensed aromatic heterobicycle, said heterobicycle consisting of 6 to 9 carbon atoms and at least one heteroatom selected in the group consisting oType: ApplicationFiled: October 11, 2006Publication date: October 29, 2009Inventors: Yves Mely, Andrey Klymchenko, Oleksandr Demchenko, Vasyl Shynkar
-
Publication number: 20090258939Abstract: Novel pyrone analogs are described which can enhance the effectiveness of a therapeutic agent when administered and/or reduce side effects caused by the administration of a therapeutic agent.Type: ApplicationFiled: July 30, 2008Publication date: October 15, 2009Inventors: Wendye Robbins, Ving Lee
-
Patent number: 7601754Abstract: Novel flavonoid compounds having anti-oxidant activity are described. Formula 1. The compounds have been shown to exhibit anti-oxidative properties in biological systems and their utility in a sunscreen or skincare composition or to treat conditions involving oxidative damage, especially curative or prophylactic treatment of Alzheimer's disease or ischaemia-reperfusion injury, is described.Type: GrantFiled: July 14, 2003Date of Patent: October 13, 2009Assignee: Antoxis LimitedInventors: Stuart Thomas Caldwell, Christopher James Bennett, Richard Charles Hartley, Donald Barton McPhail, Garry Graeme Duthie
-
Patent number: 7572919Abstract: Compounds and methods useful for treating and prevention of cancer, particularly hormone-dependent breast cancer. Provided are compounds of formula I: wherein X is selected from O, N, S, SO, SO2, and S(CH2)n, wherein n=1-10; R1 and R2 may be the same or different and are selected from H, OH, OCH3, OCH2CH3, OCH2C6H5, NH2, NHCH3, N(CH3)2, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, C(CH3)3, NO2, F, Cl, Br, CF3, SH, SCH3, SCH2CH3, OCOCH3, OCOC(CH3)3, OCOCH2COOH, and CN; and R3 is a nitrogen-containing heterocyclic ring. Also provided are method for treating or preventing cancer in a subject by administering a therapeutically effective amount of a heteroaryl-containing isoflavone, or a pharmaceutically acceptable salt or prodrug thereof, to a subject in need of treatment.Type: GrantFiled: August 26, 2005Date of Patent: August 11, 2009Assignee: The Ohio State University Research FoundationInventors: Robert W. Brueggemeier, Young-Woo Kim, John C. Hackett
-
Publication number: 20090186110Abstract: The present invention relates to the use of an extract of a plant selected from the group consisting of Psidium cattleianum, Psidium cattleianum ssp. Lucidum, Psidium guajava, Psidium guineense, Psidium littorale, Psidium molle and Psidium schiedeanum for the manufacture of a medicament for the treatment of a disease and/or condition related with and/or caused by activity of DP-IV or DP-IV like enzymes.Type: ApplicationFiled: November 8, 2006Publication date: July 23, 2009Inventor: Thomas Eidenberger
-
Patent number: 7528267Abstract: A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.Type: GrantFiled: August 1, 2005Date of Patent: May 5, 2009Assignees: Girindus America, Inc., Children's Hospital Medical CenterInventors: Kenneth David Reginald Setchell, Victor Dmitrievich Sorokin
-
Publication number: 20090099256Abstract: The present invention relate to a drug for treating circulatory insufficiency containing a benzopyran derivative represented by the following general formula (I): and/or a physiologically acceptable salt thereof as an active ingredient, wherein R1 is an alkyl group having 1 to 10 carbon atoms, or an alkenyl group having 2 to 10 carbon atoms; and any one of R2, R3, R4 and R5 is a hydroxyl group, an alkoxy group, an alkenyloxy group, an alkoxy group substituted with a hydroxyl group, or an alkoxy group substituted with a carboxy group, and the others are hydrogen atoms.Type: ApplicationFiled: October 23, 2006Publication date: April 16, 2009Applicant: ACTIVUS PHARMA CO., LTD.Inventors: Hidetsugu Takagaki, Yasuo Aoki, Mitsuteru Ishiwara
-
Publication number: 20090088580Abstract: This invention relates to a method for stabilizing quercetin by placing it in a solution containing vitamin B3 and vitamin C and assessing stability of the quercetin in the mixture.Type: ApplicationFiled: September 18, 2008Publication date: April 2, 2009Inventor: Thomas Christian Lines
-
Publication number: 20090087916Abstract: The present invention provides a method of identifying a drug candidate capable of removing peptide, oligopeptide, polypeptide or protein from fibril or aggregate, which includes measuring, in the presence of a test compound, the concentration of a soluble peptide, a soluble oligopeptide, a soluble polypeptide or a soluble protein in an equilibrium state in a solvent. Moreover, the present invention provides a dissolution promoter to remove peptide, oligopeptide, polypeptide or protein from fibril or aggregate, which contains the compound obtained by the identification method as an active ingredient.Type: ApplicationFiled: March 30, 2005Publication date: April 2, 2009Applicant: AnGesMG, Inc.Inventors: Naoyuki Sato, Masayasu Okochi, Yoshiaki Taniyama, Toshio Ogihara, Ryuichi Morishita
-
Patent number: 7507831Abstract: Various processes are disclosed for preparing protected epicatechin oligomers having (4?,8)-interflavan linkages. In one process, a tetra-O-protected epicatechin monomer or oligomer is coupled with a protected, C-4 activated epicatechin monomer in the presence of an acidic clay such as a mortmorillonite clay. In another process, a 5,7,3?,4?-benzyl protected or a 3 -acetyl-, 5,7,3?,4?-benzyl protected epicatechin or catechin monomer or oligomer is reacted with 3 -O-acetyl-4-[(2-benzothiazolyl)thio]-5,7,3?,4?-tetra-O-benzylepicatechin in the presence of silver tetrafluoroborate. In another process, two 5,7,3?,4?-benzyl protected epicatechin monomers activated with 2-(benzothiazolyl)thio groups at the C-4 positions are cross-coupled in the presence of silver tetrofluoroborate. A process is also disclosed for reacting an unprotected epicatechin or catechin monomer with 4-(benzylthio) epicatechin or catechin.Type: GrantFiled: January 11, 2006Date of Patent: March 24, 2009Inventors: Alan P. Kozikowski, Werner Tückmantel, Leo J. Romanczyk, Jr.